Cancer Research and Treatment

Cancer Research and Treatment Search

> Browse Articles > Search

Lung and Thoracic cancer

Tissue and Plasma-Based Highly Sensitive Blocker Displacement Amplicon Nanopore Sequencing for EGFR Mutations in Lung Cancer

Patinya Akkhasutthikun, Pornchai Kaewsapsak, Pattaraporn Nimsamer, Pavit Klomkliew, Suthida Visedthorn, Pragwalai Chanchaem, Chinachote Teerapakpinyo, Sunchai Payungporn, Sutima Luangdilok

Cancer Res Treat. 2024;56(2):455-463. Published online November 20, 2023 DOI: https://doi.org/10.4143/crt.2023.1108

Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma

Jae Seok Lee, Eun Kyung Kim, Kyung A Kim, Hyo Sup Shim

Cancer Res Treat. 2024;56(1):104-114. Published online July 24, 2023 DOI: https://doi.org/10.4143/crt.2023.728

Clinical Validation of the Unparalleled Sensitivity of the Novel Allele-Discriminating Priming System Technology–Based EGFR Mutation Assay in Patients with Operable Non–Small Cell Lung Cancer

Il-Hyun Park, Dae-Soon Son, Yoon-La Choi, Ji-Hyeon Choi, Ji-Eun Park, Yeong Jeong Jeon, Minseob Cho, Hong Kwan Kim, Yong Soo Choi, Young Mog Shim, Jung Hee Kang, Suzy Park, Jinseon Lee, Sung-Hyun Kim, Byung-Chul Lee, Jhingook Kim

Cancer Res Treat. 2024;56(1):81-91. Published online June 20, 2023 DOI: https://doi.org/10.4143/crt.2023.408

Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset

Ki Hyeong Lee, Byoung Chul Cho, Myung-Ju Ahn, Yun-Gyoo Lee, Youngjoo Lee, Jong-Seok Lee, Joo-Hang Kim, Young Joo Min, Gyeong-Won Lee, Sung Sook Lee, Kyung-Hee Lee, Yoon Ho Ko, Byoung Yong Shim, Sang-We Kim, Sang Won Shin, Jin-Hyuk Choi, Dong-Wan Kim, Eun Kyung Cho, Keon Uk Park, Jin-Soo Kim, Sang Hoon Chun, Jangyoung Wang, SeokYoung Choi, Jin Hyoung Kang

Cancer Res Treat. 2024;56(1):48-60. Published online June 27, 2023 DOI: https://doi.org/10.4143/crt.2023.453

EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study

Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng

Cancer Res Treat. 2023;55(3):841-850. Published online February 13, 2023 DOI: https://doi.org/10.4143/crt.2022.1438

Crossref 3

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis

Hongsik Kim, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn

Cancer Res Treat. 2023;55(2):498-505. Published online October 4, 2022 DOI: https://doi.org/10.4143/crt.2022.388

Crossref 1

Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI

Hye Ryeon Kim, Hyunji Jo, Hongsik Kim, Joohyun Hong, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Jin-Seok Ahn, Myung-Ju Ahn

Cancer Res Treat. 2023;55(1):344-349. Published online March 26, 2022 DOI: https://doi.org/10.4143/crt.2021.1603

Web of Science 1 Crossref 3

Lung and Thoracic cancer

Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation–Positive Non–Small Cell Lung Cancer

Jang Ho Lee, Eun Young Kim, Cheol-Kyu Park, Shin Yup Lee, Min ki Lee, Seong-Hoon Yoon, Jeong Eun Lee, Sang Hoon Lee, Seung Joon Kim, Sung Yong Lee, Jun Hyeok Lim, Tae-Won Jang, Seung Hun Jang, Kye Young Lee, Seung Hyeun Lee, Sei Hoon Yang, Dong Won Park, Chan Kwon Park, Hye Seon Kang, Chang Dong Yeo, Chang-Min Choi, Jae Cheol Lee

Cancer Res Treat. 2023;55(1):112-122. Published online July 19, 2022 DOI: https://doi.org/10.4143/crt.2022.381

Web of Science 3 Crossref 1

Hematologic malignancy

Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study

Seong Hyun Jeong, Seok Jin Kim, Dok Hyun Yoon, Yong Park, Hye Jin Kang, Youngil Koh, Gyeong-Won Lee, Won-Sik Lee, Deok-Hwan Yang, Young Rok Do, Min Kyoung Kim, Kwai Han Yoo, Yoon Seok Choi, Hwan Jung Yun, Jun Ho Yi, Jae-Cheol Jo, Hyeon-Seok Eom, Jae-Yong Kwak, Ho-Jin Shin, Byeong Bae Park, Shin Young Hyun, Seong Yoon Yi, Ji-Hyun Kwon, Sung Yong Oh, Hyo Jung Kim, Byeong Seok Sohn, Jong Ho Won, Se-Hyung Kim, Ho-Sup Lee, Cheolwon Suh, Won Seog Kim

Cancer Res Treat. 2022;54(4):1268-1277. Published online December 30, 2021 DOI: https://doi.org/10.4143/crt.2021.1168

Web of Science 1

Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma

Do Young Kim, Jehyun Nam, Joo-Seop Chung, Byeol Eun Jeon, Ji Hyun Lee, Jae-Cheol Jo, Sang-Woo Kim, Ho-Jin Shin

Cancer Res Treat. 2022;54(4):1256-1267. Published online December 31, 2021 DOI: https://doi.org/10.4143/crt.2021.944

Web of Science 2 Crossref 2

Breast cancer

Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based Regimens

Helen P. Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, Anna Batistatou, Kyriaki Papadopoulou, Mattheos Bobos, Anthoula Asimaki-Vlachopoulou, Sofia Chrisafi, Kitty Pavlakis, Kyriakos Chatzopoulos, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Dimitrios Bafaloukos, Eleni Res, Pavlos Papakostas, Angelos Koutras, Vassiliki Kotoula, George Fountzilas

Cancer Res Treat. 2022;54(4):1053-1064. Published online November 17, 2021 DOI: https://doi.org/10.4143/crt.2021.748

Web of Science 2 Crossref 1

Lung and Thoracic cancer

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non–Small Cell Lung Cancer

Noeul Kang, Ki Hwan Kim, Byeong-Ho Jeong, Kyungjong Lee, Hojoong Kim, O Jung Kwon, Myung-Ju Ahn, Jeonghee Cho, Ho Yun Lee, Sang-Won Um

Cancer Res Treat. 2022;54(3):817-826. Published online November 9, 2021 DOI: https://doi.org/10.4143/crt.2021.822

Web of Science 2 Crossref 2

Acquired Resistance Mechanism of EGFR Kinase Domain Duplication to EGFR TKIs in Non–Small Cell Lung Cancer

Chaelin Lee, Miso Kim, Dong-Wan Kim, Tae Min Kim, Soyeon Kim, Sun-Wha Im, Yoon Kyung Jeon, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo

Cancer Res Treat. 2022;54(1):140-149. Published online May 3, 2021 DOI: https://doi.org/10.4143/crt.2021.385

Web of Science 3 Crossref 4

Lung cancer

A Phase II Trial of Osimertinib as the First-Line Treatment of Non–Small Cell Lung Cancer Harboring Activating EGFR Mutations in Circulating Tumor DNA: LiquidLung-O-Cohort 1

Cheol-Kyu Park, Hyun-Ju Cho, Yoo-Duk Choi, In-Jae Oh, Young-Chul Kim

Cancer Res Treat. 2021;53(1):93-103. Published online September 21, 2020 DOI: https://doi.org/10.4143/crt.2020.459

Web of Science 3 Crossref 3

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation

Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn

Cancer Res Treat. 2020;52(4):1288-1290. Published online June 22, 2020 DOI: https://doi.org/10.4143/crt.2020.278

Web of Science 17 Crossref 7

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide

Gun Min Kim, Joo Hoon Kim, Ji Heung Kim, Young Up Cho, Seung Il Kim, Seho Park, Hyung Seok Park, Ji Ye Kim, Joohyuk Sohn

Cancer Res Treat. 2019;51(2):812-818. Published online September 19, 2018 DOI: https://doi.org/10.4143/crt.2018.383

Web of Science 4 Crossref 3

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Seonggyu Byeon, Youjin Kim, Sung Won Lim, Jang Ho Cho, Sehoon Park, Jiyun Lee, Jong-Mu Sun, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Cancer Res Treat. 2019;51(2):623-631. Published online July 23, 2018 DOI: https://doi.org/10.4143/crt.2018.151

Web of Science 41 Crossref 35

EGFR Mutation Is Associated with Short Progression-Free Survival in Patients with Stage III Non-squamous Cell Lung Cancer Treated with Concurrent Chemoradiotherapy

Song Ee Park, Jae Myoung Noh, You Jin Kim, Han Sang Lee, Jang Ho Cho, Sung Won Lim, Yong Chan Ahn, Hongryull Pyo, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Cancer Res Treat. 2019;51(2):493-501. Published online June 18, 2018 DOI: https://doi.org/10.4143/crt.2018.125

Web of Science 25 Crossref 27

Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Tae Min Kim, Keun-Wook Lee, Do-Youn Oh, Jong-Seok Lee, Seock-Ah Im, Dong-Wan Kim, Sae-Won Han, Yu Jung Kim, Tae-You Kim, Jee Hyun Kim, Hyesun Han, Woo Ho Kim, Yung-Jue Bang

Cancer Res Treat. 2018;50(3):835-842. Published online August 29, 2017 DOI: https://doi.org/10.4143/crt.2017.303

Web of Science 58 Crossref 55

Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer

Youngjoo Lee, Ki Hyeong Lee, Geon Kook Lee, Soo-Hyun Lee, Kun Young Lim, Jungnam Joo, Yun Jung Go, Jin Soo Lee, Ji-Youn Han

Cancer Res Treat. 2017;49(4):1001-1011. Published online January 13, 2017 DOI: https://doi.org/10.4143/crt.2016.546

Web of Science 38 Crossref 33

Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status

Youngjoo Lee, Ji-Youn Han, Sung Ho Moon, Byung-Ho Nam, Kun Young Lim, Geon Kook Lee, Heung Tae Kim, Tak Yun, Hye Jin An, Jin Soo Lee

Cancer Res Treat. 2017;49(4):981-989. Published online January 6, 2017 DOI: https://doi.org/10.4143/crt.2016.522

Web of Science 12 Crossref 12

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis

Sook-Hee Hong, Yeon-Sil Kim, Ji Eun Lee, In-ho Kim, Seung Joon Kim, Daehee Han, Ie Ryung Yoo, Yang-Guk Chung, Young-Hoon Kim, Kyo-Young Lee, Jin-Hyoung Kang

Cancer Res Treat. 2016;48(3):1110-1119. Published online January 6, 2016 DOI: https://doi.org/10.4143/crt.2015.289

Web of Science 6 Crossref 7

Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells

Mi Hyun Kang, Sung Ung Moon, Ji Hea Sung, Jin Won Kim, Keun Wook Lee, Hye Seung Lee, Jong Seok Lee, Jee Hyun Kim

Cancer Res Treat. 2016;48(1):355-364. Published online March 5, 2015 DOI: https://doi.org/10.4143/crt.2014.260

Web of Science 8 Crossref 7

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

Bhumsuk Keam, Dong-Wan Kim, Jin Hyun Park, Jeong-Ok Lee, Tae Min Kim, Se-Hoon Lee, Doo Hyun Chung, Dae Seog Heo

Cancer Res Treat. 2013;45(3):178-185. Published online September 30, 2013 DOI: https://doi.org/10.4143/crt.2013.45.3.178

Crossref 9

Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

Jae Cheol Lee, Seung Hun Jang, Kye Young Lee, Young-Chul Kim

Cancer Res Treat. 2013;45(2):79-85. Published online June 30, 2013 DOI: https://doi.org/10.4143/crt.2013.45.2.79

Crossref 14

Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy

Seung Tae Kim, Kyong Hwa Park, Jun Suk Kim, Sang Won Shin, Yeul Hong Kim

Cancer Res Treat. 2013;45(1):55-62. Published online March 31, 2013 DOI: https://doi.org/10.4143/crt.2013.45.1.55

Crossref 12

No Association of Vascular Endothelial Growth Factor-A (VEGF-A) and VEGF-C Expression with Survival in Patients with Gastric Cancer

Soo Jung Lee, Jong Gwang Kim, Sang Kyun Sohn, Yee Soo Chae, Joon Ho Moon, Shi Nae Kim, Han-Ik Bae, Ho Young Chung, Wansik Yu

Cancer Res Treat. 2009;41(4):218-223. Published online December 31, 2009 DOI: https://doi.org/10.4143/crt.2009.41.4.218

Crossref 17

Improving Conventional or Low Dose Metronomic Chemotherapy with Targeted Antiangiogenic Drugs

Robert S. Kerbel

Cancer Res Treat. 2007;39(4):150-159. Published online December 31, 2007 DOI: https://doi.org/10.4143/crt.2007.39.4.150

Crossref 37

Inhibition of Phorbol Ester-induced Mouse Skin Tumor Promotion and COX-2 Expression by Celecoxib: C/EBP as a Potential Molecular Target

Kyung-Soo Chun, Joydeb Kumar Kundu, Kwang-Kyun Park, Won-Yoon Chung, Young-Joon Surh

Cancer Res Treat. 2006;38(3):152-158. Published online June 30, 2006 DOI: https://doi.org/10.4143/crt.2006.38.1.152

Crossref 10

Prognostic Significance of Immunohistochemical Expression of EGFR and C-erbB-2 Oncoprotein in Curatively Resected Gastric Cancer

Hong Suk Song, Young Rok Do, In Ho Kim, Soo Sang Sohn, Kun Young Kwon

Cancer Res Treat. 2004;36(4):240-245. Published online August 31, 2004 DOI: https://doi.org/10.4143/crt.2004.36.4.240

Crossref 18